Presentation is loading. Please wait.

Presentation is loading. Please wait.

Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome  Iskra Pusic,

Published byΑντώνης Παπακώστας Modified over 6 years ago

Similar presentations

Presentation on theme: "Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome  Iskra Pusic,"— Presentation transcript:

1 Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome  Iskra Pusic, Jaebok Choi, Mark A. Fiala, Feng Gao, Matthew Holt, Amanda F. Cashen, Ravi Vij, Camille N. Abboud, Keith E. Stockerl- Goldstein, Meghan A. Jacoby, Geoffrey L. Uy, Peter Westervelt, John F. DiPersio  Biology of Blood and Marrow Transplantation  Volume 21, Issue 10, Pages (October 2015) DOI: /j.bbmt Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Cohorts' characteristics.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 (A) Disease-free survival (DFS) and overall survival (OS). (B) Relapse and non-relapse mortality. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 Effect of decitabine on the frequency of Tregs, CD4 T cells, CD8 T cells, B cells, and NK cells in the peripheral blood at stated time points (C1D1: cycle 1 day 1; C1D5: cycle 1 day 5; C3D1: cycle 3 day 1; C3D5: cycle 3 day 5; END: end of study). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

5 Figure 4 Effect of decitabine on the absolute number of Tregs, CD4 T cells, CD8 T cells, B cells, and NK cells in the peripheral blood and stated time points (C1D1: cycle 1 day 1; C1D5: cycle 1 day 5; C3D1: cycle 3 day 1; C3D5: cycle 3 day 5; END: end of study). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

6 Figure 5 DNA methylation status at the FOXP3 locus of cohort 4 (15 mg/m2/days). Shown are means and standard deviations of DNA methylation status of 16 CpGs of each patient in cohort 4 (patients 18-22). Pt indicates patient; C, cycle; D, day. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome  Iskra Pusic,"

Similar presentations

Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated.

Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated.
Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.
Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant 

Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant 
Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors  Kenneth.

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors  Kenneth.
Allogeneic Stem Cell Transplantation in Myelofibrosis

Allogeneic Stem Cell Transplantation in Myelofibrosis
Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched.

Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched.
Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis  Armin Rashidi,

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis  Armin Rashidi,
Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous.

Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous.
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Feasible Outcomes of T Cell–Replete Haploidentical Stem Cell Transplantation with Reduced-Intensity Conditioning in Patients with Myelodysplastic Syndrome 

Feasible Outcomes of T Cell–Replete Haploidentical Stem Cell Transplantation with Reduced-Intensity Conditioning in Patients with Myelodysplastic Syndrome 
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 
Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.

Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.
CD34-Selected, T Cell Depleted Haploidentical Donor Peripheral Blood Stem Cell (PBSC) Transplantation in Children with Malignant (MD) and Non-Malignant.

CD34-Selected, T Cell Depleted Haploidentical Donor Peripheral Blood Stem Cell (PBSC) Transplantation in Children with Malignant (MD) and Non-Malignant.
The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.

The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.
Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation  Iskra Pusic, Shi Yuan Jiang,

Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation  Iskra Pusic, Shi Yuan Jiang,
Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions  Darius Sairafi, Mats Remberger, Michael.

Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions  Darius Sairafi, Mats Remberger, Michael.
Upfront Allogeneic Blood Stem Cell Transplantation for Patients with High-Risk Myelodysplastic Syndrome or Secondary Acute Myeloid Leukemia Using a FLAMSA-

Upfront Allogeneic Blood Stem Cell Transplantation for Patients with High-Risk Myelodysplastic Syndrome or Secondary Acute Myeloid Leukemia Using a FLAMSA-
Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation  David A. Jacobsohn, Brad Hewlett, Elaine Morgan,

Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation  David A. Jacobsohn, Brad Hewlett, Elaine Morgan,

Similar presentations

Ads by Google